Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,728 across all filing types
Latest filing 2014-06-10 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
重大资产重组停牌公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Kunming Pharmaceutical Group Co., Ltd. regarding a trading suspension due to a proposed major asset restructuring. It mentions the stock suspension starting June 11, 2014, for up to 30 days to ensure fair disclosure and prevent abnormal stock price fluctuations. The announcement references ongoing audit, evaluation, legal, and financial advisory work related to the restructuring. This is clearly an announcement about a capital restructuring event and related trading halt, not a full report or detailed financial statements. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and it is an announcement, not a full report, so it is not an Annual Report or Interim Report. Confidence is high given the explicit mention of major asset restructuring and trading suspension.
2014-06-10 Chinese
关于股权激励事宜的进展公告
Transaction in Own Shares Classification · 95% confidence The document is a short announcement regarding the progress of an equity incentive plan, specifically about the repurchase and reclassification of shares related to restricted stock awards. It mentions a board meeting resolution and a previous announcement. The content focuses on share repurchase and equity incentive details, not a full financial report or detailed management discussion. The document length is only 561 characters, indicating it is a brief announcement rather than a comprehensive report. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers company buyback or issuance of shares related to equity incentives.
2014-06-04 Chinese
关于延期派发2013年度现金红利的提示性公告
Notice of Dividend Amount Classification · 95% confidence The document is a short announcement (746 characters) from Kunming Pharmaceutical Group Co., Ltd. regarding the delay in the distribution of the 2013 annual cash dividend. It references the 2013 annual shareholders' meeting decision on profit distribution and explains the reason for the delay due to regulatory changes in dividend payment processing dates. The document does not contain financial statements or detailed financial data but is an announcement about dividend payment timing. According to the classification rules, announcements about dividend amounts, payment dates, and related details fall under the category 'Notice of Dividend Amount' (DIV).
2014-05-29 Chinese
北京德恒（昆明）律师事务所关于公司2014年股权激励计划所涉限制性股票授予相关事宜的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2014 equity incentive plan involving restricted stock grants for Kunming Pharmaceutical Group Co., Ltd. It references relevant laws, regulatory approvals, company board meetings, and compliance with stock incentive regulations. The document is a legal opinion on the equity incentive plan and stock grants, not a financial report, earnings release, or regulatory filing. It is not an announcement of voting results or a proxy statement. The content is focused on legal compliance and procedures related to stock incentives, which fits best under Regulatory Filings (RNS) as it is a legal opinion document related to corporate governance and compliance but does not fit other more specific categories like MANG or CGR. The document length is about 5,000 characters, and it contains substantive legal content rather than just an announcement or certification. Therefore, the best classification is Regulatory Filings (RNS).
2014-05-28 Chinese
七届十一次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the supervisory board (监事会) of Kunming Pharmaceutical Group Co., Ltd. It details the decisions made in a supervisory board meeting regarding stock incentive repurchase and restricted stock grant dates. The document is an official announcement of board-level decisions rather than a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a regulatory certification or voting result announcement. It fits best under Board/Management Information (MANG) as it relates to internal governance decisions and board resolutions.
2014-05-28 Chinese
七届二十次董事会决议暨关于2014年股权激励计划所涉限制性股票授予相关事宜的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the board resolution on the 2014 equity incentive plan involving restricted stock grants. It includes specifics about the stock grant date, quantities, recipients, legal and audit opinions, and the impact on share capital structure. The content focuses on the board's decisions and approvals related to the equity incentive plan, including legal and supervisory opinions, rather than presenting a full financial report or earnings data. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a proxy solicitation or voting results announcement. The document is a formal announcement of board resolutions and related information about management equity incentives, which fits best under Board/Management Information (MANG). The document length and detail confirm it is not a brief announcement or a report publication notice. Therefore, the classification is MANG with high confidence.
2014-05-28 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.